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Editorial Comment
Clinical Research on Children in
The 1990s*
ARTHUR GARSON, JR., MD, FACC
Houston, Texas
In the 1970s and 1980s, a great deal of clinical research was
published (my own work included) that might be viewed
differently in the 1990s. It is worthwhile to examine the
research principles that have evolved, and especially their
application to children, before assessing the report by Mehta
and Chidambaram (1) in this issue of the Journal.
Clinical research on children. Children are little adults in
some ways, and not in others. Some clinical research on
children, especially studies of drugs and devices, is based on
findings demonstrated previously in adults. Therefore, the
original research question can be as simple as, What differ-
ences are observed between the responses of children and
adults? However, in providing such a narrow focus for an
investigation, we miss the opportunity to learn about chil-
dren. Any research project, especially one involving inva-
sive testing, should provide data that not only are specific to
the question being studied, but also can be generalized to
other childen. For example, from a drug study, one should
learn how children of different ages absorb, metabolize,
distribute and excrete drugs in general, using a specific drug
as a model.
When the research question involves testing specific
hypotheses based on data presented in other investigations,
such as those performed in adults, it is important to conduct
a truly prospective study (a retrospective study identifies
areas for future prospective studies). In undertaking a pro-
spective study, there is a certain responsibility to obtain
from every patient, if at all possible, every piece of data that
is sought. Therefore, the data to be evaluated must be
chosen carefully and based on hypotheses (one might say
that the difference between fishing and hypothesis testing is
that with hypothesis testing, you guess what kind of fish you
are going to catch). In assessing the specific data to be
collected, one must choose the control group carefully. In
children especially, the confounding variables of growth and
development must be considered. Rarely are historical con-
trol subjects acceptable because, in the space of 1 year or
less, a problem such as supraventricular tachycardia may
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disappear or worsen spontaneously in response to a child's
growth and development. In planning a prospective study,
the number of subjects necessary to answer each question
must be calculated and the calculation must be based on a
straightforward formula of estimated variance.
We owe it to the children to perform rigidly controlled
protocols. In conducting clinical research studies on antiar-
rhythmic drugs in children, I have found that it is not the
patients or the parents who are noncompliant but the doctors
who "let it go." We can and must perform double-blind,
placebo-controlled studies. Although the children may not
know the difference between drug and placebo, parents often
understand the difference and influence their children in
subtle ways. Parents must be taught by the nursing and
physician staff to be careful, objective observers. They need
to understand that children may show subtle signs of toxicity
such as irritability or listlessness (it is difficult for 14-month
old children to tell parents that they have a headache).
Reliance for evaluation on the presence or absence of
symptoms even through the teenage years may be inade-
quate in children. More objective methods of evaluation
should be sought, including more frequent observation by
trained professionals and more frequent laboratory testing.
Parallel study designs are more likely than sequential designs
to yield meaningful results because the natural history ofany
disease changes with growth and development.
Assessment of the need for invasive studies such as blood
drawing or even electrophysiologic study should be based on
the risklbenefit ratio in a manner similar to that used in
adults. If sequential blood drawing for measurement of
pharmacokinetic variables in necessary to answer a ques-
tion, and the pharmacokinetic data are needed to answer a
specific question about a specific child as well as for general
use in learning about children, the data should be obtained.
In plannning such invasive studies, however, it should be
remembered that children are impressionable and have ex-
tremely good memories, but they may not understand the
relation of the testing to their overall benefit or to the benefit
to human understanding. Therefore, in children the discom-
fort of testing must be weighed more importantly on the risk
side of the risk/benefit ratio.
We have been extremely fortunate to have access to one
of several Clinical Research Centers supported by the Na-
tional Institutes of Health and designed specifically for
children. Because the entire nursing staff in such centers is
oriented toward making the children who are being studied
as comfortable as possible, the adverse effects of hospital-
ization and testing are minimized. These centers are vital to
the performance of safe and productive research in children.
These centers provide the important atmosphere of concern
for the patient; they also require patients or parents, or both,
to sign a consent form, thus forcing physicians to declare
when they are doing research and to demonstrate to the
parents (and in many cases to the child) the exact nature of
the research and its costs and its benefits.
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We have a responsibility to the children and their parents
to make valid conclusions based on the data obtained. A
study should not be completed or reported if it is based on
small subgroups of patients that are too small to allow
meaningful comparisons. The inferences based on these
small groups may be misleading and the data subject to a
type II error.
The present study. The major conclusion in the study of
Mehta and Chidambaram (1) is that nadolol is a safe and
effective agent in the management of supraventricular tachy-
cardia in children; the arrhythmia in 23 of 26 patients was
well controlled. It is likely that such good results were the
result of the administration of nadolol; nonetheless, a more
rigorous study design with a parallel placebo group might
have improved the study. The second conclusion-that the
long-term efficacy can be predicted by the short-term re-
sponse to intravenous nadolol or propranolol-may require
more data. Of the 27 children, 7 received intravenous
nadolol and 6received intravenous propranolol. The concor-
dance of results again supports the conclusion, but in a
prospective study, the inclusion of larger numbers in each
subgroup would have been helpful.
Conclusions. In recent years, the art of designing a pro-
spective clinical research study has become a science. There
are numerous examples of extremely well done studies that
have allowed us to reach important conclusions that have
helped many people. Many of these studies have been in
adult patients and some have been in children. If we as
pediatric cardiologists are to be taken seriously as members
of the scientific community, we must follow the examples of
excellence in clinical research. We are being judged by a new
standard.
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